Recommendation of the President – Blenrep (belantamab mafodotin)
On 6 March 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 26/2026 on the reimbursement of the medicinal product Blenrep (belantamab mafodotin) under the B.54 drug program. “Treatment of patients with multiple myeloma (ICD-10: C90.0)”